Citalopram 20mg (DrugBank: Citalopram)
6 diseases告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
6 | パーキンソン病 | 1 |
8 | ハンチントン病 | 0 |
13 | 多発性硬化症/視神経脊髄炎 | 0 |
18 | 脊髄小脳変性症(多系統萎縮症を除く。) | 0 |
46 | 悪性関節リウマチ | 0 |
127 | 前頭側頭葉変性症 | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04497168 (ClinicalTrials.gov) | January 2021 | 29/7/2020 | Citalopram as a Posterior Cortical Protective Therapy in Parkinson Disease | Citalopram as a Posterior Cortical Protective Therapy in Parkinson Disease | Parkinson Disease | Drug: Citalopram 20mg;Drug: Placebo | University of Michigan | National Institute on Aging (NIA) | Not yet recruiting | 65 Years | N/A | All | 58 | Phase 2 | United States |